Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS
Home/The Filing Wire/Cel-Sci Corporation/ 10-Q

Quarterly Report · 10-Q

Cel-Sci Corporation

CVMNYSE_AMERICANEQUITYCurrent

Quarterly Report

Filed Aug 14, 2026Accepted Aug 14, 2026, 4:16 PM EDTCIK 725363Accession 0001654954-26-007657
View company →Permanent SEC source ↗
Share

Company context

We are a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. We are currently focused on the development of the following product candidates and technologies with emphasis on Multikine:

Current securities

CVMNYSE_AMERICAN · EQUITY · Current
Historical securities (1)
CVM.WSNYSE_AMERICAN · WARRANT · Historical · closed Oct 9, 2018

Recent company filings

  1. S-8 filingSep 3, 2026
  2. Submission of Matters to a Vote of Security HoldersAug 17, 2026
  3. ARS filingJul 2, 2026
  4. DEF 14A filingJul 2, 2026
  5. Entry into a Material Definitive Agreement · Other EventsJun 16, 2026

Registered securities in this filing

CEL-SCI CORPORATION · 10-Q · Filed 2026-08-14

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock

Symbol
CVM
Exchange
NYSE
Classification
COMMON
Status
Current
Filing context

Context: From2025-10-01to2026-06-30

Dimensions: Not supplied

Accession 000165495426007657 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence
As filedOpen full document ↗

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.